Search
Vamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48676] Vamorolone was approved by the FDA in October 2023 for the management of DMD in patients ≥2 years of age. … [L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505]
Bromhexine
go.drugbank.com/drugs/DB09019ApprovedInvestigationalIt was introduced into the market in 1963, and is widely available as an over-the-counter drug in many countries. … [A233240] Recently, bromhexine and its metabolite [ambroxol] have garnered interest for the potential prevention and treatment of COVID-19 due to their interactions with cell receptors in the lungs.
Mixtures: TUSSIONEX DUO JARABE, Hosolvon DM Elixir (Sugar Free)Denileukin diftitox
go.drugbank.com/drugs/DB00004ApprovedInvestigational[A264349, L51254] Denileukin diftitox was originally approved by the FDA in 1999 for the treatment of cutaneous T-cell lymphoma (CTCL),[A264339, L51264] making it the first fusion protein cytotoxin … [A264344] In 2014, it was withdrawn voluntarily from the market due to manufacturing issues; however, the biologics license application (BLA) for denileukin diftitox was resubmitted, and it was approved
Efbemalenograstim alfa
go.drugbank.com/drugs/DB18704ApprovedInvestigational[A33650,A262172] On November 22, 2023, efbemalenograstim alfa was approved by the FDA under the brand name Ryzneuta for the treatment of chemotherapy-induced neutropenia in adult patients with non-myeloid … Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration
Defibrotide
go.drugbank.com/drugs/DB04932ApprovedInvestigationalIt is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
Carboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigational[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248] … Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.
Products: BLASTOCARB RU, BLASTOCARB RU 450 MG (SOLUCION INYECTABLE)Marstacimab
go.drugbank.com/drugs/DB17725ApprovedInvestigational[L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant. … [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency.
Testosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIt was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. … Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester.
Ziprasidone
go.drugbank.com/drugs/DB00246ApprovedInvestigational[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. … [A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.
Categories: Dopamine D2 Receptor AntagonistsProducts: ZIPRASIDONE MYLAN GENERICSRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigational[A262066] On November 15th, 2023, the FDA approved repotrectinib under the brand name Augtyro for the treatment of locally advanced or metastatic ROS1-Positive NSCLC. … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the